Short answer
Erasca, Inc. (ERAS) filed its Q2 2026 10-Q quarterly report on Aug 11, 2026 for the quarter ended Jun 30, 2026.
Q2 2026 key financials · XBRL
- Net income
- −$44M
- −30.1% YoY · +76.0% QoQ
- EPS (diluted)
- −$0.14
- −16.7% YoY · +76.7% QoQ
Source: XBRL data from the Erasca, Inc. (ERAS) Q2 2026 10-Q on SEC EDGAR. USD.
Erasca, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0; no products approved or revenue generated
- Net loss $44.1M vs $33.9M YoY for quarter ended June 30, 2026
- Best program ERAS-0015: 57% uORR at 32 mg QD in 2L+ KRAS G12X PDAC
- Cash, equivalents, and marketable securities $384.3M at June 30, 2026
- July offering added $593.5M net; expenses and operating losses expected to increase substantially
Risk Factors
- New IP infringement risk: RevMed’s April 24, 2026 letter alleges ERAS-0015 infringes U.S. Patent No. 12,409,225
- Most material legal update: RevMed demanded cessation of ERAS-0015 activities and comparative disclosures involving RMC-6236
- New securities litigation risk: June 10, 2026 class action alleges federal securities-law violations against Erasca and officers
- New governance litigation risk: August 2026 derivative complaint alleges fiduciary-duty and federal securities-law violations
- Operational impact: Potential injunctions, damages, licensing needs, or development-plan changes for ERAS-0015
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Erasca, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.